SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (444)11/11/2018 12:35:09 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 507
 
After revisiting SITC presentation, nektar.com

and clearing my mind/hart....I continue to believe that 214 is approvable cancer drug. When that would be relieved to street and shorts...bits me. NKTR SP may continue to experience short pressure, in current environment which stock does not?, so patience and position timing may be way to play (IF/who can swallow that approach).